Synapse - Yelena Janjigian

Results (403)

BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes

Meeting Abstract

Abdelfattah, S.; Harada, G.; Patel, S.; Artz, O.; Yaeger, R.; Johannet, P.; Harrold, E.; Walch, H. S.; Argiles, G.; Rousseau, B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Meeting Abstract

Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results

Meeting Abstract

Janjigian, Y. Y.; Kawazoe, A.; Xu, J.; Lonardi, S.; Metges, J. P.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y.; Bilici, M.; Lowery, M. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Pembrolizumab in HER2-positive gastric cancer

Research Letter

Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yañez, P.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y.; more...
New England Journal of Medicine (2024)

Fulltext@MSK | Save

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649

Meeting Abstract

Elimova, E.; Shitara, K.; Moehler, M. H.; Ajani, J. A.; Shen, L.; Garrido, M.; Gallardo, C.; Wyrwicz, L. S.; Yamaguchi, K.; Cleary, J. M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors

Meeting Abstract

Raufi, A. G.; Goyal, L.; Smyth, E.; Szekeres, P.; Petrone, M.; Hobson, R.; Thress, K.; Origuchi, M.; Nehra, J.; Brown, J. S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors

Meeting Abstract

Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Association of ERBB2 extrachromosomal DNA (ecDNA) with first-line HER2-targeted treatment outcomes in advanced esophagogastric adenocarcinoma (EGC)

Meeting Abstract

Tsai, C.; Suman, S.; Chu, C.; Chou, J. F.; Krein, P. M.; Capanu, M.; Ilson, D. H.; Ku, G. Y.; Janjigian, Y. Y.; Drilon, A. E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-Year follow-up of the phase III CheckMate 649 trial